Four years after announcing an ambitious — and often ridiculed — project to create a glucose-sensing contact lens along with Novartis subsidiary Alcon, Alphabet's Verily is throwing in the towel, the company announced in a blog post today. It will continue to work on two other medical contact lens projects, aimed at presbyopia and cataract surgery recovery.
"Our clinical work on the glucose-...
All of the diverse operations of Verily, the life sciences technology company that began its life as Google X Life Sciences, can be summed up with a simple sentence: We should be treating our bodies at least as well as we treat our cars.
At the Health 2.0 Fall Conference in Santa Clara this week, Verily Chief Technology Officer Brian Otis spoke with Health 2.0 cofounder and CEO Dr. Indu Subaya on...
Google and Novartis are working on two smart contact lenses, and news broke this week about both of them: A new patent application sheds light on how Google might power its glucose-sensing contact lens, just a week after partner Novartis told a Swiss newspaper it was on track for human trials in 2016 of an autofocus lens for presbyopia patients.
Patent applications don't always presage exactly...
Just seven months after announcing its ambitious contact lens program, Google has announced a partnership with Novartis eye care division Alcon to license its still-largely-theoretical "smart lens" to the Swiss pharma company.
"We are looking forward to working with Google to bring together their advanced technology and our extensive knowledge of biology to meet unmet medical needs," Novartis CEO...
According to a report in the Economist, pharmaceuticals company Novartis' $24 million investment in intelligent medicine startup Proteus Biomedical may be just as important in the long run as Novartis' $50 billion takeover of eye-care firm, Alcon. Proteus Biomedical's venture capital round actually brought in $25.4 million, which makes us wonder if the difference came from an additional...
